Radicava ORS

Drug MITSUBISHI TANABE PHARMA AMERICA, INC.
Total Payments
$18,824
Transactions
6
Doctors
6
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $3,850 1 1
2022 $14,974 5 5

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $14,954 4 79.4%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,850 1 20.5%
Food and Beverage $20.15 1 0.1%

Top Doctors Receiving Payments for Radicava ORS

Doctor Specialty Location Total Records
, MD Clinical Neurophysiology Loma Linda, CA $5,500 1
, M.D Neuromuscular Medicine Chattanooga, TN $4,240 1
, MD Clinical Neurophysiology Saint Louis, MO $3,850 1
, MD Neurology Seattle, WA $3,850 1
, MD, PHD Neuromuscular Medicine Chicago, IL $1,364 1
, MD Neurology Cordova, TN $20.15 1

About Radicava ORS

Radicava ORS is a drug associated with $18,824 in payments to 6 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is MITSUBISHI TANABE PHARMA AMERICA, INC..

Payment data is available from 2022 to 2023. In 2023, $3,850 was paid across 1 transactions to 1 doctors.

The most common payment nature for Radicava ORS is "Consulting Fee" ($14,954, 79.4% of total).